Oncotarget

Research Papers:

The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer

Sonya D. Coaxum, Jessica Tiedeken, Elizabeth Garrett-Mayer, Jeffrey Myers, Steven A. Rosenzweig and David M. Neskey _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:22991-23007. https://doi.org/10.18632/oncotarget.14967

Metrics: PDF 1841 views  |   HTML 2484 views  |   ?  


Abstract

Sonya D. Coaxum1, Jessica Tiedeken2, Elizabeth Garrett-Mayer3, Jeffrey Myers4, Steven A. Rosenzweig2, David M. Neskey1,2

1Department of Otolaryngology, Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA

2Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA

3Department of Public Health Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA

4Department of Head & Neck Surgery, M.D. Anderson Medical Center, Houston, TX, USA

Correspondence to:

David M. Neskey, email: Neskey@musc.edu

Keywords: head and neck squamous cell carcinoma, TP53, non-muscle myosin IIA, tumor suppressor

Received: July 18, 2016    Accepted: January 10, 2017    Published: February 01, 2017

ABSTRACT

Over 300,000 patients develop squamous cell carcinoma of the head and neck (HNSCC) worldwide with 25-30% of patients ultimately dying from their disease. Currently, molecular biomarkers are not used in HNSCC but several genes have been identified including mutant TP53 (mutp53). Our recent work has identified an approach to stratify patients with tumors harboring high or low risk TP53 mutations. Non-muscle Myosin IIA (NMIIA) was recently identified as a tumor suppressor in HNSCC. We now demonstrate that low MYH9 expression is associated with decreased survival in patients with head and neck cancer harboring low-risk mutp53 but not high-risk mutp53. Furthermore, inhibition of NMIIA leads to increased invasion in cells harboring wildtype p53 (wtp53), which was not observed in high-risk mutp53 cells. This increased invasiveness of wtp53 following NMIIA inhibition was associated with reduced p53 target gene expression and was absent in cells expressing mutp53. This reduced expression may be due, in part, to a decrease in nuclear localization of wtp53. These findings suggest that the tumor suppressor capability of wtp53 is dependent upon functional NMIIA and that the invasive phenotype of high-risk mutp53 is independent of NMIIA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14967